Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections. Open forum infectious diseases Sweeney, D. A., Tuyishimire, B., Ahuja, N., Beigel, J. H., Beresnev, T., Cantos, V. D., Castro, J. G., Cohen, S. H., Cross, K., Dodd, L. E., Erdmann, N., Fung, M., Ghazaryan, V., George, S. L., Grimes, K. A., Hynes, N. A., Julian, K. G., Kandiah, S., Kim, H. J., Levine, C. B., Lindholm, D. A., Lye, D. C., Maves, R. C., Oh, M. D., Paules, C., Rapaka, R. R., Short, W. R., Tomashek, K. M., Wolfe, C. R., Kalil, A. C. 2023; 10 (5): ofad205

Abstract

We performed a secondary analysis of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) randomized controlled trial and found that baricitinib was associated with a 50% reduction in secondary infections after controlling for baseline and postrandomization patient characteristics. This finding provides a novel mechanism of benefit for baricitinib and supports the safety profile of this immunomodulator for the treatment of coronavirus disease 2019.

View details for DOI 10.1093/ofid/ofad205

View details for PubMedID 37206623

View details for PubMedCentralID PMC10191442